India Cardiac Marker Testing Market (2026-2031)
The India Cardiac Marker Testing Market was valued at $113.8 Million in 2026 and projected to reach to $213.3 Million by 2031, representing a compound annual growth rate of 13.4%. India's cardiac marker testing market is positioned for substantial growth through 2031, driven by the nation's escalating cardiovascular disease prevalence and expanding healthcare infrastructure.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
India Cardiac Marker Testing Market Trends and Insights
- This growth trajectory reflects India's rising burden of cardiovascular disease, increasing healthcare infrastructure investment, and growing adoption of point-of-care testing across urban and semi-urban regions.
- India's market expansion is driven by a large patient population, improving diagnostic awareness, and government initiatives to strengthen cardiac care accessibility. The 13.4% compound annual growth rate (CAGR) positions India as one of the fastest-growing cardiac marker testing markets in the Asia Pacific region.
- India's healthcare sector modernization, coupled with rising disposable incomes and private hospital expansion, is accelerating demand for rapid, accurate cardiac biomarker assays.
- Between 2026 and 2031, India is expected to see significant penetration of troponin, BNP, and myoglobin testing across tertiary care centers, diagnostic laboratories, and emergency departments, supporting earlier detection and improved patient outcomes..
Key Market Statistics
- CAGR (2026-2031) 13.4% CAGR
- Market Size, 2026 ~USD 113.8 Million
- Forecast, 2031 ~USD 213.3 Million
- Country India
India Cardiac Marker Testing Market Overview
Rapid Market Expansion :
India's cardiac marker testing market is projected to grow from USD 113.8 million in 2026 to USD 213.3 million by 2031, representing a robust 13.4% CAGR, outpacing the global growth rate of 10.3%.
Rising Cardiovascular Disease Burden :
India faces an escalating prevalence of cardiovascular diseases driven by urbanization, lifestyle changes, and aging demographics, creating sustained demand for cardiac diagnostic testing across urban and semi-urban healthcare facilities.
Point-of-Care Testing Adoption :
Growing adoption of point-of-care cardiac marker testing in India's emerging healthcare infrastructure enables faster diagnosis and treatment decisions, particularly in resource-constrained settings and rural diagnostic centers.
Healthcare Infrastructure Investment :
Increased government and private sector investment in India's healthcare infrastructure, coupled with diagnostic center expansion, is driving accessibility and utilization of cardiac marker testing services nationwide.
India Cardiac Marker Testing Market Dynamics
- The market benefits from increasing awareness of early cardiac diagnosis, rising disposable incomes in urban centers, and government initiatives promoting preventive healthcare.
- Point-of-care testing technologies are gaining traction across diagnostic centers, hospitals, and clinics, democratizing access to cardiac testing beyond metropolitan areas. The forecast period will witness intensified competition among diagnostic providers and testing equipment manufacturers targeting India's growing middle class and healthcare modernization initiatives.
- Strategic partnerships between international diagnostic companies and Indian healthcare providers, combined with regulatory support for diagnostic innovation, will accelerate market penetration.
- The convergence of digital health platforms with cardiac testing services presents additional growth opportunities, particularly in semi-urban and emerging markets..
Related Ecosystem
In Vitro Diagnostics
Medical Devices
Key Takeaways
- India's cardiac marker testing market is valued at USD 113.8 million in 2026 and is forecast to grow to USD 213.3 million by 2031, representing an accelerated 13.4% CAGR.
- India's market growth is fueled by rising cardiovascular disease prevalence, expanding private healthcare networks, and increasing adoption of rapid diagnostic testing in emergency and critical care settings.
- Point-of-care testing and high-sensitivity troponin assays are gaining traction across India's diagnostic landscape, driven by improved healthcare accessibility and diagnostic awareness.
- India's cardiac marker testing market is positioned as a high-growth segment within Asia Pacific, supported by demographic trends, healthcare modernization, and government health initiatives.
Cardiac Marker Testing Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | OTHER CARDIAC BIOMARKERS (Biomarker Type) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 10.3% from 2026 to 2031 |
| Largest Segment | SINGLEPLEX ASSAY (Assay Format) |
| Market Size Base Year (Billions) | ~USD 5.55 (2026) |
| Revenue Forecast (Billions) | ~USD 9.06 (2031) |
| Segments Covered | Product, Technology, Type, Indication, Biomarker Type, Point Of Testing, Assay Format, End User |
India Cardiac Marker Testing Market Report Segmentation
8 segment dimensions are covered across the global market.
By Product
- Instruments
- Reagents & Kits
By Technology
- Clinical Chemistry
- Immunoassay
- Immunoassays
By Type
- Chemiluminescence
- Contract Testing Laboratories
- Elisa
- Hospital Laboratories
- Immunofluorescence
- Lateral Flow Immunoassay
- Reference Laboratories
By Indication
- Acute Coronary Syndrome
- Atherosclerosis
- Congestive Heart Failure
- Ischemia
- Myocardial Infarction
By Biomarker Type
- Brain Natriuretic Peptide
- Creatinine Kinase-Mb
- High-Sensitivity C-Reactive Protein
- Homocysteine
- Myoglobin
- Other Cardiac Biomarkers
- Troponin I & T
By Point Of Testing
- Lab Tests
- Poc Tests
By Assay Format
- Multiplex Assay
- Multiplex Assays
- Singleplex Assay
- Singleplex Assays
By End User
- Academic Institutes
- Laboratory Testing Facilities
- Point-Of-Care Testing
INDIA: CARDIAC MARKER TESTING MARKET, BY END USER, 2024–2031
| Segment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC INSTITUTES | 11.9 | 12.5 | 14 | 15.7 | 17.8 | 20.1 | 22.9 | 26 | 13.2 |
| LABORATORY TESTING FACILITIES | 89.3 | 92.3 | 102.4 | 113.9 | 127.1 | 142.4 | 160 | 180 | 11.9 |
| POINT-OF-CARE TESTING | 39.8 | 42 | 47.6 | 54 | 61.5 | 70.4 | 80.9 | 93 | 14.3 |
| TOTAL | 141 | 146.8 | 164 | 183.6 | 206.4 | 233 | 263.8 | 299 | 12.8 |
Target Audience
- Diagnostic Equipment Manufacturers : Manufacturers need India-specific market data to develop localized product strategies, identify distribution partnerships, and prioritize R&D investments in point-of-care cardiac testing technologies for the high-growth Indian market.
- Healthcare Providers & Hospital Networks : Hospital administrators and diagnostic center operators require market insights to justify capital expenditure on cardiac testing infrastructure, benchmark service offerings, and optimize diagnostic service portfolios for competitive advantage.
- Private Equity & Investment Firms : Investors evaluating healthcare opportunities in India need validated market sizing and growth projections to assess investment returns, identify acquisition targets, and structure deals in the cardiac diagnostics sector.
- Pharmaceutical & Biotech Companies : Companies developing cardiac biomarkers and testing solutions require India market data to guide commercialization strategies, regulatory planning, and partnership development with local healthcare stakeholders.
- Healthcare Consultants & Advisors : Management consultants and healthcare advisors need India-specific market intelligence to support client strategy development, competitive analysis, and market entry planning for cardiac diagnostics businesses.
Key Companies in the India Cardiac Marker Testing Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ABBOTT LABORATORIES | United States | Public Company | Diagnostic Products,Medical Devices,Nutritional Products, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing hardware, consumables, and services),Life Sciences (instruments, reagents, and genomic medicines),Diagnostics (clinical instruments, consumables, and software), |
| SIEMENS HEALTHINEERS AG | Germany | Public Company | Imaging,Diagnostics,Varian (Oncology), |
| THERMO FISHER SCIENTIFIC | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| BIO-RAD LABORATORIES | United States | Public Company | Life Science,Clinical Diagnostics, |
| BIOMéRIEUX SA | France | Public Company | Clinical microbiology (culture media, VITEK, VITEK MS, API, ETEST, BACT/ALERT),Molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, NUCLISENS, EPISEQ),Immunoassay and sepsis (VIDAS, Hybiome CLIA), |
| BECTON, DICKINSON AND COMPANY | United States | Public Company | Medical Essentials (needles, syringes, vascular access, sharps safety),Connected Care (infusion, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery systems), |
| DIASORIN SPA | Italy | Public Company | Immunodiagnostics – LIAISON XL/XS infectious and GI disease panels,Immunodiagnostics – endocrinology, metabolic, tumor markers, oncology,Molecular diagnostics – Simplexa and LIAISON PLEX respiratory, |
| REVVITY | United States | Public Company | Diagnostics (prenatal, newborn, infectious disease, autoimmune, specialty IVD),Life science reagents, assay platforms, and genomic workflows,Instruments, imaging, detection systems, and software, |
| TOSOH CORPORATION | Japan | Public Company | Basic chemicals (caustic soda, sodium bicarbonate, calcium hypochlorite, related chlor-alkali),Petrochemicals and polymers (VCM, PVC, polyethylene, EVA, synthetic rubber, functional polymers),Polyurethanes and related intermediates (MDI, HDI, polyisocyanates, polyols, PU resins), |
| QUIDEL CORPORATION | United States | Public Company | Labs (Clinical Chemistry & Immunoassay),Transfusion Medicine,Point of Care, |
| GUANGZHOU WONDFO BIOTECH CO., LTD. | China | Public Company | Rapid test kits (COVID-19, infectious disease, fertility, drug-of-abuse, tumor markers, STD),Immunofluorescence platform (Finecare FIA Meter X2 and related assays),Chemiluminescence platform, |
ABBOTT LABORATORIES
Abbott Laboratories is a major United States-based public company founded in 1888 with approximately 115,000 employees, operating as a diversified healthcare organization.
DANAHER CORPORATION
Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees, operating across multiple industrial and life sciences sectors.
SIEMENS HEALTHINEERS AG
Siemens Healthineers AG is a German public company founded in 1896 with 72,369 employees, specializing in medical technology and healthcare solutions.
THERMO FISHER SCIENTIFIC
Thermo Fisher Scientific is a United States-based public company founded in 1956 with 125,000 employees, serving as a global leader in life sciences and laboratory services.
BIO-RAD LABORATORIES
Bio-Rad Laboratories is a United States-based public company founded in 1952 with 7,450 employees, specializing in life science research and clinical diagnostics products.
BIOMéRIEUX SA
bioMérieux SA is a French public company founded in 1963 with 14,894 employees, focused on in vitro diagnostics and microbiology testing solutions.
BECTON, DICKINSON AND COMPANY
Becton, Dickinson and Company is a United States-based public company founded in 1897 with 72,000 employees, specializing in medical devices, diagnostics, and biosciences.
DIASORIN SPA
DiaSorin SpA is an Italian public company founded in 1968 with 3,242 employees, specializing in in vitro diagnostics and immunodiagnostic solutions.
REVVITY
Revvity is a United States-based public company founded in 1937 with 11,000 employees, providing analytical instruments and life sciences solutions.
TOSOH CORPORATION
Tosoh Corporation is a Japanese public company founded in 1935 with 14,850 employees, operating across specialty chemicals, pharmaceuticals, and diagnostics sectors.
QUIDEL CORPORATION
Quidel Corporation is a United States-based public company founded in 1979 with 6,500 employees, specializing in rapid diagnostic testing solutions.
GUANGZHOU WONDFO BIOTECH CO., LTD.
Guangzhou Wondfo Biotech Co., Ltd. is a Chinese public company founded in 1992 with 2,443 employees, focused on in vitro diagnostic products and solutions.
Reasons to Buy this Report
- Market Size Validation : Access precise market valuation data for India's cardiac marker testing sector with verified 2026 baseline (USD 113.8M) and 2031 forecast (USD 213.3M), enabling accurate business planning and investment decisions.
- Growth Trajectory Insights : Understand India's 13.4% CAGR outperformance versus global 10.3% growth, identifying the country as a high-priority market for diagnostic companies, investors, and healthcare providers seeking expansion opportunities.
- Regional Adoption Patterns : Gain detailed intelligence on point-of-care testing adoption across urban and semi-urban India, informing product positioning, distribution strategies, and market entry approaches for diagnostic solutions.
- Competitive Landscape Analysis : Benchmark competitive positioning within India's cardiac testing market, identifying key players, market consolidation trends, and partnership opportunities in this rapidly expanding healthcare segment.
- Strategic Investment Guidance : Make informed capital allocation decisions with comprehensive India-specific market data, supporting feasibility studies, business case development, and stakeholder presentations for cardiac diagnostics ventures.
Frequently asked questions
What is the current size of India's cardiac marker testing market?
India's cardiac marker testing market is valued at USD 113.8 million in 2026 and is expected to grow to USD 213.3 million by 2031.
What is the projected growth rate for India's cardiac marker testing market?
India's cardiac marker testing market is projected to grow at a compound annual growth rate (CAGR) of 13.4% from 2026 to 2031.
What factors are driving growth in India's cardiac marker testing market?
Growth in India's cardiac marker testing market is driven by rising cardiovascular disease prevalence, expanding private healthcare infrastructure, increasing diagnostic awareness, and government health initiatives supporting cardiac care accessibility.
Which cardiac markers are most commonly tested in India?
High-sensitivity troponin, B-type natriuretic peptide (BNP), and myoglobin are among the most commonly tested cardiac markers in India's diagnostic laboratories and healthcare facilities.
How is India's cardiac marker testing market positioned within Asia Pacific?
India's cardiac marker testing market is one of the fastest-growing segments in Asia Pacific, driven by demographic trends, healthcare modernization, and increasing adoption of point-of-care testing technologies.
RESEARCH METHODOLOGY
The objective of the study is to analyze the key market dynamics, including drivers, opportunities, restraints, challenges, and strategies of key players. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players. The competitive landscape of the cardiac marker testing market analyzes market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches are used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation have been used.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
BREAKDOWN OF PRIMARY INTERVIEW PARTICIPANTS
Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = > USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.
|
COMPANY NAME |
DESIGNATION |
|
Abbott Laboratories (US) |
Sales Manager |
|
F. Hoffmann-La Roche AG (Switzerland) |
Product Manager |
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the cardiac marker testing market. These methods were also used extensively to estimate the sizes of various market subsegments. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research
- The revenues generated by leading players operating in the cardiac marker testing market have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
The research methodology used to estimate the market size includes the following:
Data Triangulation
After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Cardiac marker testing refers to the measurement and quantification of biological parameters, such as enzymes, hormones, and proteins that are released into the bloodstream or show altered levels in response to cardiac conditions. These tests serve as indicators of the heart's physiological and pathophysiological status and are used for the early detection, risk stratification, and monitoring of cardiovascular diseases, including acute coronary syndrome (ACS), acute myocardial infarction (AMI), cardiac ischemia, and congestive heart failure (CHF).
Key Stakeholders
- Product Manufacturers, Distributors, and Suppliers
- Diagnostic Laboratories and Point-of-care Testing Centers
- Research Laboratories and CROs
- Ambulatory Testing Centers
- Contract Testing Laboratories
- Academic Universities and Medical Research Centers
- Research & Development (R&D) Centers
Report Objectives
- To define, segment, and forecast the cardiac marker testing market by product, technology, indication, biomarker type, point of testing, assay format, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To benchmark players within the market using the proprietary Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
- To study the impact of AI on the market, along with the macroeconomic outlook for each region
Available customizations:
MarketsandMarkets offers the following customizations for this market report.
Country Information
- Additional country-level analysis of the cardiac marker testing market
Company profiles
- Additional five company profiles of players operating in the cardiac marker testing market.
Product Analysis
- Product matrix, which provides a detailed comparison of the product portfolio of each company in the cardiac marker testing market
Get the Full Cardiac Marker Testing Market Report
Full forecast, segment splits, and company analysis for all Cardiac Marker Testing Market.
- US Cardiac Marker Testing Market
- Canada Cardiac Marker Testing Market
- UK Cardiac Marker Testing Market
- Germany Cardiac Marker Testing Market
- France Cardiac Marker Testing Market
- Italy Cardiac Marker Testing Market
- Spain Cardiac Marker Testing Market
- China Cardiac Marker Testing Market
- Japan Cardiac Marker Testing Market
- Australia Cardiac Marker Testing Market
- South Korea Cardiac Marker Testing Market
- Brazil Cardiac Marker Testing Market
- Mexico Cardiac Marker Testing Market
- Rest Of Europe Cardiac Marker Testing Market
- Rest Of Asia Pacific Cardiac Marker Testing Market
- Rest Of Latin America Cardiac Marker Testing Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report